Omeros (OMER) Rating Increased to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research report report published on Saturday morning.
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Other analysts also recently issued research reports about the company. Seaport Global Securities initiated coverage on Omeros in a research note on Thursday, July 12th. They issued a buy rating and a $30.00 target price on the stock. HC Wainwright set a $34.00 price target on Omeros and gave the stock a buy rating in a research report on Monday, August 6th. ValuEngine upgraded Omeros from a hold rating to a buy rating in a research report on Saturday. Maxim Group reiterated a buy rating and set a $25.00 price target on shares of Omeros in a research report on Monday, May 7th. Finally, BidaskClub upgraded Omeros from a hold rating to a buy rating in a research report on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $27.56.
Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). The firm had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter last year, the firm earned ($0.33) EPS. The firm’s revenue was down 90.1% on a year-over-year basis. research analysts predict that Omeros will post -2.45 EPS for the current fiscal year.
In other Omeros news, VP Marcia S. Kelbon sold 40,723 shares of the stock in a transaction that occurred on Friday, July 27th. The stock was sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the transaction, the vice president now owns 219,645 shares of the company’s stock, valued at $4,735,546.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Marcia S. Kelbon sold 4,277 shares of the stock in a transaction that occurred on Thursday, July 12th. The shares were sold at an average price of $21.48, for a total value of $91,869.96. Following the transaction, the vice president now directly owns 188,922 shares of the company’s stock, valued at approximately $4,058,044.56. The disclosure for this sale can be found here. Corporate insiders own 12.10% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. BlueMountain Capital Management LLC acquired a new position in shares of Omeros during the second quarter valued at approximately $118,000. Quad Cities Investment Group LLC acquired a new position in shares of Omeros during the second quarter valued at approximately $161,000. Belpointe Asset Management LLC acquired a new position in shares of Omeros during the second quarter valued at approximately $204,000. Claraphi Advisory Network LLC acquired a new position in shares of Omeros during the first quarter valued at approximately $134,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Omeros during the second quarter valued at approximately $274,000. 45.94% of the stock is owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.